Context: Recent genetic studies have identified genetic variants associated with age at pubertal onset. Whereas genome-wide association studies reported associations of several hundred genetic variants with timing of self-reported age at menarche, a recent clinical study focused on genetic variation affecting follicle-stimulating hormone action and clinically determined age at thelarche. The observations appear to be incongruent, as effect sizes varied substantially among the studies. Alternatively, this may point to a differential impact of specific genetic loci on distinct pubertal events.
P ubertal timing varies largely between individuals, reflecting, namely, a genetic influence but also nutritional, environmental, and socioeconomic factors (1, 2). Recently, large-scale genome-wide association studies (GWAS) provided important insight into the genetic etiology of female pubertal timing. Based on recall of age at menarche, almost 400 genetic loci have been shown to be associated with this late pubertal event, explaining ;7.4% of the population variance (3, 4).
The most frequent initial clinical hallmark of female pubertal onset is, however, thelarche, i.e., the formation of breast buds. In a clinical setting, this event is used for the assessment of pubertal onset. In a recent study, our group demonstrated a strong association of the genetic variation of follicle-stimulating hormone (FSH) action, i.e., FSHB c.2211G.T and FSHR c.229G.A, with thelarche (5) . GWAS underpinned the influence of genetic variation of FSH action on female reproductive aging (6) and fertility parameters (7, 8) ; however, the association with age at menarche exhibited only a minor effect size (4).
In light of these diverging results of genetic variation of FSH action on thelarche and menarche, we analyzed the association of the genetic variation of FSHB and FSHR with both age at thelarche and menarche in a cohort of 1478 healthy Danish girls. Furthermore, we included the top signals with the largest effect size among the common single nucleotide polymorphisms (SNPs) identified by recent GWAS on age at menarche (LIN28B, INHA, MKRN3, TMEM38B, and ZNF483) (3).
Materials and Methods

Healthy Danish girls
The participants comprised healthy Danish girls and adolescents from the Copenhagen area recruited in three population-based cohort studies. A brief description of the cohorts follows:
(1) The Copenhagen Puberty Study (9, 10) 
Study population
The study population comprises white girls between 5 and 19 years with clinical pubertal staging; body mass index (BMI) data; FSHB c.2211G.T (rs10835638), FSHR c.229G.A (rs1394205), and FSHR c.2039A.G (rs6116) genotype; and/ or LIN28B (rs7759938), INHA (rs4141153), MKRN3 (rs12148769), TMEM38B (rs10453225), and ZNF483 (rs10980921). Of the 2307 girls, a total of 829 girls were excluded as a result of age ,5 or .19 years (n = 484), missing pubertal staging (neither thelarche nor menarche data available; n = 4), one or both parents originated from a non-European country (n = 96), missing BMI data (n = 2), or no DNA available (n = 243). The remaining 1478 girls (Copenhagen Puberty Study, n = 872; Copenhagen Mother-Child Cohort, n = 606) were included. Ninety out of the 872 girls of the Copenhagen Puberty Study were followed longitudinally, with visits every 6 months [median number of visits: nine (range two to 12)], whereas 523 out of 606 girls of the Copenhagen Mother-Child Cohort were followed longitudinally [median number of visits: three (range two to six)].
The association of FSHB c.2211G.T and FSHR c.229G. A with age at thelarche [one dataset contained exclusively girls aged eight to 13 years (Cohort A + C), n = 964; another dataset included only the girls of the Copenhagen Puberty Study that were followed longitudinally (Cohort B), n = 78] has been reported previously (5, 14) . New data represent additional girls, aged five to 19 years, of the Copenhagen Mother-Child Cohort and the cross-sectional part of the Copenhagen Puberty Study, as well as timing of menarche and LIN28B, INHA, MKRN3, TMEM38B, and ZNF483 genotypes.
Clinical examination and questionnaires
Clinical examinations were performed by trained professionals (three pediatric fellows examined the children in Cohorts A and B. Eight young pediatric fellows were trained by experienced pediatric endocrinologists (A.J. and K.M.M.) to evaluate pubertal development in Cohort C. Pubertal staging was assessed by examination of breast development, according to Tanner´s classification (15) . Breast stage 2 ( "elevation of breast and papilla as a small mound, enlargement of areola diameter") was considered to be a marker of thelarche. Selfreported age at menarche was obtained through a questionnaire. The reliability of clinical staging of breast development, according to Tanner, was tested in a subset of 100 girls from Cohort C. The sensitivity and specificity for breast inspection and palpation to detect the presence of glandular breast tissue were 96% and 95%, respectively (16).
Genotyping
Venous blood was used for isolation of genomic DNA using the QuickGene-810 nucleic acid isolation system (Fujifilm; Life Science Products, Tokyo, Japan). All genetic variants were analyzed using the KASP™ SNP genotyping assays (LGC Genomics, Middlesex, UK) using a competitive polymerase chain reaction at the Department of Growth and Reproduction Rigshospitalet, University of Copenhagen (Copenhagen, Denmark). Genotyping was performed for the following:
, and ZNF483 (rs10980921) using specific primers (designed by LGC Genomics). The previously mentioned variants are adjacent to the genes coding for the following products: FSH beta subunit (FSHB), FSH receptor (FSHR), Lin-28 homolog B (LIN28B), inhibin alpha subunit (INHA), makorin ring finger protein 3 (MKRN3), transmembrane protein 38B (TMEM38B), and zinc finger protein 483 (ZNF483).
Statistical analyses
To estimate the mean age [95% confidence interval (CI)] at a pubertal event, we performed probit analyses (PROC LIFE-REG; SAS Institute, Cary, NC), integrating left-, right-, and interval-censored observations and A) "Breast stage $2" and B) "Menarche," with yes/no as the binomial response variable. Longitudinal data of girls encountering a pubertal event during follow-up were included in the analyses as interval censored data. If a girl had not encountered a pubertal event at her last examination (or at her only examination if seen once), then her age at examination was used as right-censored data. If a girl had encountered a pubertal event at her first examination, her age at examination was used as left-censored data. BMI data were standardized by applying World Health Organization age-specific BMI scores [BMI z scores (zBMI)] (17). If longitudinal data were available, then a mean of all individual zBMI was calculated. In the probit analyses, age at thelarche/ menarche was adjusted for zBMI as a continuous variable.
Interactions between categorical variables were tested via the LIFEREG MODEL statement. Given our previous observations of a combined effect of FSHB c.2211G.T and FSHR c.229G.A on the age at thelarche (5), we additionally examined the effect of this genotype combination (minor allele count). When evaluating genotype effects, we used an additive model, assuming a cumulative allele effect in a dose-dependent manner (18) . This model was also used to assess the effect of genotype combinations. P # 0.05 was considered statistically significant. 
Ethical considerations
Results
When evaluated separately, FSHR c.229G.A was significantly associated with age at thelarche (P = 0.006; b = 0.22 years per zBMI, 95% CI: 0.06 to 0.38 years) but not with age at menarche (P = 0.90). FSHB c.2211G.T and FSHR c.2039A.G were neither associated with age at thelarche (P = 0.38 and P = 0.18, respectively) nor with age at menarche (P = 0.83 and P = 0.79, respectively). The combined FSHB c.2211G.T and FSHR c.229G.A minor allele count was associated with thelarche (P = 0.007) but not menarche (P = 0.96; Fig. 1 ; Table 1 ). Genetic variation of LIN28B (rs7759938) was associated with age at thelarche (P = 0.0003) and age at menarche (P = 0.005; Fig. 1 ; Table 1 ; all adjusted for zBMI; noncorrected data are shown in Supplemental Table 1 ). We did not observe significant association of genetic variations of INHA (rs4141153), MKRN3 (rs12148769), TMEM38B (rs10453225), and ZNF483 (rs10980921) with age at thelarche or menarche (Supplemental Table 1 ). The mean zBMI of all girls was 0.03 (standard deviation: 0.93, range: 22.88 to +2.92). zBMI was significantly associated with age at thelarche (P , 0.001; b = 20.29 years per zBMI, 95% CI: 20.39 to 20.18 years) and age at menarche (P , 0.001; b = 20.38 years per zBMI, 95% CI: 20.46 to 20.29 years). The LIN28B genotype (rs7759938) did not interact significantly with the FSHB c.2211G.T and FSHR c.229G.A (rs10835638 and rs1394205, respectively) minor allele count (thelarche analysis: P = 0.10; menarche analysis: P = 0.74) or zBMI (thelarche analysis: P = 0.38; menarche analysis: P = 0.24).
Discussion
In this population-based study comprising 1478 healthy Danish girls, we observed a differential impact of genetic variations on timing of thelarche and menarche. Whereas FSHB c.2211G.T and FSHR c.229G.A were associated with age at thelarche but not with age at menarche, LIN28B (rs7759938) was associated with both thelarche and menarche. To our knowledge, this is the first report of a differential impact of distinct genetic loci on different female pubertal milestones. Recent large-scale GWAS significantly advanced our understanding of female puberty. However, the outcome parameter, usually used as proxy for pubertal onset in GWAS, i.e., menarche (3, 4), differs from the actual proxy used in the clinical assessment of onset of female puberty, i.e., thelarche. Secular trends have been shown to affect differentially age at thelarche vs age at menarche, suggesting differences in their regulation (9) . In a subgroup of the current study, we previously demonstrated a relatively strong effect of the combined FSHB c.2211G.T and FSHR c.229G.A minor allele count on age at thelarche (5), whereas recent GWAS demonstrated a substantial but much weaker effect of FSHB c.2211G.T on age at menarche (3, 4). Although each of the previously mentioned studies exclusively focused on a single pubertal milestone, the results may appear incongruent. Our present study demonstrates that these results are not incongruent but indicative of a differential impact of genetic variation on pubertal events: we observed a substantial effect of FSHB c.2211G.T and FSHR c.229G.A on age at thelarche but not age at menarche. Whereas recent GWAS consistently showed an effect of FSHB c.2211G.T on age at menarche [20. 04 years per allele (3)], our study was clearly underpowered to observe an association of such small effect size. At the same time, our results concerning LIN28B are in line with recent GWAS, which observed a strong association of genetic variations of LIN28B with timing of thelarche (selfreported data: "More likely breast development at 10 years") (19) and menarche (3, 4, 19) . The effect size of genetic variations of INHA, MKRN3, TMEM38B, and ZNF483 may be too small to be picked up by our study, whereas FSHR c.2039A.G does not appear to be associated with age at thelarche/menarche neither in the current study nor in previous GWAS.
Comparable to our current observations in girls, we recently reported a strong association of FSHB c.2211G.T and FSHR c.229G.A with age at testicular growth, i.e., the initial event of male puberty, in boys (20) .
This association was not observed in a GWAS using age at voice break as proxy (21), thus suggesting a differential impact on distinct pubertal events in boys as well.
Our hypothesis suggests that factors (almost) exclusively acting on thelarche are associated with altered length of pubertal transition, i.e., the interval between thelarche and menarche. In the limited longitudinal data available, we have not been able to detect an effect of FSHB/FSHR SNPs on the speed of pubertal progression in healthy girls (22) . However, larger datasets may reveal effects of combination of genotypes.
Previous tissue enrichment analyses underlined the key role of the central nervous system in pubertal onset, as assessed by age at menarche, but also peripheral factors were shown to play a role (3, 4). We speculate that factors predominantly involved in the reactivation of the hypothalamic-pituitary-gonadal (HPG) axis at a central level, i.e., hypothalamic level, may be associated with timing of all pubertal milestones, whereas this might not be the case for more peripherally acting target-tissuespecific factors. In line with this theory, LIN28B, presumably centrally acting, and FSHB/FSHR, peripherally acting, appear to exert their effect independently, as they did not interact significantly.
Data on ovarian morphology in healthy girls suggest that genetic variations of FSH action, i.e., FSHB c.2211G.T and FSHR c.229G.A, affect follicle growth, including subsequent estrogen production (14, 23) . Subsequently, thelarche, a primarily estrogen-driven process, might be postponed, as a result of a higher FSH threshold, delaying the initial FSH-induced estrogen production. By contrast, with accelerating HPG axis activation, an increasing FSH stimulus in later puberty may overcome subtle differences in basal FSH production and receptor response. Furthermore, menarche is a more complex process involving numerous factors responsible for mature negative feedback of the HPG axis, as well as the growth hormone (24) or insulinlike growth factor (25). The strength of the current study is the large sample size, including both clinically assessed outcomes and data from questionnaires based on short-term recall. This provides robust information on both age at thelarche and menarche from a population-based study. Limitations include a potential recall bias of age at menarche. Previous studies highlighted the accuracy of short-term recall of age at menarche (26) compared with long-term recall (27) .
In conclusion, we observed a differential impact of distinct genetic variants on timing of thelarche and menarche in healthy girls and stressed the importance of precise endpoint definition in genetic association studies.
